Serous cystadenocarcinoma ovary – Diagnostics – Overview of Information and Clinical Research

Diagnosing serous cystadenocarcinoma of the ovary involves multiple steps and methods, from recognizing early symptoms to advanced imaging and laboratory tests that help doctors understand the type and extent of the disease. Early detection can significantly improve outcomes, though many cases are found at later stages due to vague symptoms.

Introduction: When to Seek Diagnostic Testing

Serous cystadenocarcinoma of the ovary, particularly the high-grade form, is the most common type of ovarian cancer. It accounts for approximately 75% of all epithelial ovarian cancers, which make up nearly 90% of all ovarian cancer cases.^[1] Understanding when to seek medical evaluation is an important first step in diagnosis.

Women should consider undergoing diagnostic testing when they experience persistent symptoms that last for more than two weeks. Common warning signs include bloating, abdominal pain, feeling full quickly after eating, frequent urination, unexplained weight loss, discomfort in the pelvic area, fatigue, back pain, and changes in bowel habits such as constipation.^[4] These symptoms can be subtle and are often mistaken for less serious conditions like digestive problems or stress, which is why many women don’t recognize them as potential signs of cancer right away.

Because ovarian cancer occurs most commonly in women aged 65 and older, increasing age is considered an important risk factor. However, younger women, particularly those with certain genetic mutations or family histories of breast or ovarian cancer, should also be vigilant about symptoms.^[12] Women who have had breast cancer face a threefold higher risk of developing high-grade serous carcinoma, while those with pelvic inflammatory disease also have increased susceptibility to this specific subtype.^[5]

⚠️ Important

Because symptoms of serous ovarian cancer are often vague and easily confused with other conditions, many cases are not diagnosed until the disease has reached an advanced stage. Only about 20% of ovarian cancer cases are found early, when treatment is most effective. If you experience the symptoms mentioned above persistently for two weeks or more, it’s important to consult your doctor promptly rather than waiting for symptoms to worsen.

Classic Diagnostic Methods

Once symptoms raise concern, doctors use a combination of physical examinations, imaging tests, and blood tests to determine whether ovarian cancer is present and to distinguish it from other conditions that might cause similar symptoms. No single test can definitively diagnose ovarian cancer on its own, so multiple approaches are typically used together to build a complete picture.

Pelvic Examination

The diagnostic process often begins with a pelvic exam, during which a doctor inserts gloved fingers into the vagina while pressing on the abdomen with the other hand. This technique, called palpation, helps the doctor feel the ovaries and other pelvic organs to check for abnormal masses, swelling, or other irregularities. The doctor also visually examines the external genitalia, vagina, and cervix during this examination.^[10] While a pelvic exam can detect abnormalities, it cannot confirm whether a mass is cancerous or benign, so additional testing is always necessary.

Imaging Tests

Imaging tests create pictures of the inside of the body and are crucial for evaluating the size, shape, and structure of the ovaries, as well as detecting any tumors or abnormal growths. Several types of imaging may be used depending on what information doctors need.

Ultrasound is often one of the first imaging tests ordered when ovarian cancer is suspected. A pelvic ultrasound uses sound waves to create images of the reproductive organs. A transvaginal ultrasound, where a small probe is inserted into the vagina, provides especially detailed images of the ovaries and surrounding structures. This test can help doctors determine whether a mass is solid (which may indicate cancer) or filled with fluid (which is more likely to be a benign cyst).^[10]

Computed tomography (CT) scans use X-rays taken from multiple angles to create detailed cross-sectional images of the abdomen and pelvis. CT scans can reveal the extent of disease spread, showing whether cancer has moved beyond the ovaries to nearby organs, lymph nodes, or other parts of the body. This information is essential for staging the cancer and planning treatment.^[10]

Blood Tests

Blood tests serve two purposes in diagnosing ovarian cancer: they can detect specific proteins associated with cancer (called tumor markers), and they can assess overall organ function to help doctors understand a patient’s general health status.

The most commonly used tumor marker test for ovarian cancer is the CA-125 test, which measures levels of a protein called cancer antigen 125 in the blood. This protein is often found at higher levels on the surface of ovarian cancer cells. However, CA-125 levels can also be elevated due to other noncancerous conditions such as endometriosis, uterine fibroids, pelvic inflammatory disease, or even normal menstruation. Therefore, an elevated CA-125 level alone doesn’t prove cancer exists, but it provides valuable information when combined with other diagnostic findings.^[10] After treatment, CA-125 testing is frequently used to monitor for recurrence, as rising levels can indicate the cancer has returned.^[7]

Additional blood tests check how well the liver, kidneys, and other organs are functioning, which helps doctors plan safe and effective treatment approaches.^[10]

Surgical Biopsy

While imaging and blood tests provide strong clues, a definitive diagnosis of serous cystadenocarcinoma requires examining actual tissue under a microscope. This is typically done through a surgical procedure where doctors remove an ovary or a portion of suspicious tissue for detailed analysis. This process, called a biopsy, allows pathologists to confirm whether cancer cells are present and to determine the specific type and grade of the tumor.^[10]

When high-grade serous carcinoma cells are viewed under a microscope, they appear highly abnormal compared to healthy cells. The cancer is classified as Grade 3, meaning the cells are poorly differentiated—they don’t have a clear structure or pattern and tend to grow rapidly. This lack of organization indicates that the tumor cells behave abnormally and spread aggressively.^[1]

Genetic Testing

For some patients, genetic testing of a blood sample is recommended to look for inherited gene changes that increase cancer risk. Mutations in genes called BRCA1 and BRCA2 are found in approximately 21-25% of high-grade serous ovarian carcinoma cases. People born with these mutations have a significantly higher risk of developing ovarian cancer and breast cancer throughout their lives.^[2]^[5]

Knowing about genetic mutations has multiple benefits. First, it helps doctors make more informed treatment decisions, as patients with BRCA mutations may respond differently to certain therapies. Second, it provides important information for family members, who may also carry the same genetic changes and could benefit from enhanced screening or preventive measures. Finally, research has shown that patients with BRCA1 or BRCA2 mutations actually have better survival odds compared to those without these mutations.^[2]

Beyond BRCA testing, approximately 96% of high-grade serous ovarian carcinomas show mutations in a gene called TP53. This gene normally produces a protein that prevents cancer development by acting as a tumor suppressor. When TP53 is mutated, cells lose this protective mechanism, allowing cancer to develop more easily.^[2]^[5]

⚠️ Important

Genetic testing results can have implications not just for your own health management but also for your biological relatives. If you test positive for BRCA1, BRCA2, or other hereditary cancer mutations, your siblings, children, and other blood relatives may have a 50% chance of carrying the same mutation. Sharing this information with family members allows them to consider their own testing and potentially benefit from enhanced surveillance or preventive strategies.

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments for cancer and often have specific requirements that patients must meet to participate. These requirements exist to ensure patient safety and to help researchers obtain clear, meaningful results. Understanding the diagnostic tests and criteria used for clinical trial enrollment can help patients and doctors determine whether participation might be beneficial.

Confirmed Diagnosis and Staging

Before enrolling in a clinical trial for serous ovarian cancer, patients must have a confirmed diagnosis through biopsy showing the presence of high-grade serous carcinoma. The exact type of epithelial ovarian cancer matters because different subtypes (such as clear cell, mucinous, or endometrioid ovarian cancers) may behave differently and respond to different treatments. Many trials specifically focus on high-grade serous carcinoma because it’s the most common form.^[1]

Clinical trials also typically require detailed staging information, which describes how far the cancer has spread. Staging is determined through a combination of imaging tests (such as CT scans), surgical findings, and biopsy results. This information helps match patients to trials testing treatments appropriate for their disease stage.

Performance Status Assessment

Most clinical trials assess a patient’s overall physical condition and ability to carry out daily activities, called performance status. This evaluation helps determine whether a patient is healthy enough to tolerate the investigational treatment being tested. Doctors use standardized scales to rate how well patients can function, from being fully active to requiring complete bed rest.

Organ Function Tests

Blood tests measuring kidney function, liver function, and bone marrow health are standard requirements for most clinical trials. These tests ensure that patients’ organs are working well enough to safely process and eliminate the investigational drugs. Tests typically include measurements of kidney function (such as creatinine levels), liver enzymes, and blood cell counts.^[10]

Biomarker Testing

Many modern clinical trials require specific biomarker testing to identify which patients are most likely to benefit from the treatment being studied. For serous ovarian cancer trials, this frequently includes:

BRCA mutation testing to identify patients with hereditary genetic changes, as some treatments specifically target cancers with these mutations.
TP53 mutation analysis, since the vast majority of high-grade serous carcinomas carry these mutations, which can affect treatment response.^[2]
Gene expression profiling, which examines patterns of gene activity in tumor cells. Research has identified that certain gene expression patterns correlate with better or worse survival outcomes. Patients with the poorest survival gene expression pattern have been shown to live 23% shorter periods than other patients.^[2]
HRD (Homologous Recombination Deficiency) testing, which identifies tumors with specific DNA repair defects that may respond to particular targeted therapies.

Imaging Requirements

Clinical trials typically require baseline imaging studies before treatment begins and at regular intervals during the study. This allows researchers to accurately measure tumor size and monitor how tumors respond to treatment over time. CT scans are most commonly used, though some trials may also use MRI scans or PET scans depending on the specific research questions being investigated.

Prior Treatment History

Many clinical trials are designed for patients whose cancer has returned after initial treatment (called recurrent or persistent disease). For these trials, detailed documentation of all previous treatments is required, including the specific chemotherapy drugs used, when they were given, and how the cancer responded. The timing of recurrence is particularly important—cancers that return within six months of completing platinum-based chemotherapy are classified as platinum-resistant, while those recurring after six months are called platinum-sensitive. Different trials may focus on one group or the other.^[7]

Some trials, particularly those testing completely new types of therapy, may be designed for patients in earlier stages of treatment or even as initial (upfront) therapy. These trials have different requirements than those for recurrent disease.

Prognosis and Survival Rate

Prognosis

The outlook for women with serous cystadenocarcinoma of the ovary depends heavily on several factors, with the stage at diagnosis being one of the most significant. Unfortunately, most cases of high-grade serous ovarian carcinoma are diagnosed at advanced stages (III or IV), when the cancer has already spread beyond the ovaries to other areas of the abdomen or distant organs. This happens because early-stage disease rarely causes noticeable symptoms, and there are currently no effective screening tests available to detect ovarian cancer before symptoms appear.

When serous ovarian cancer is diagnosed at an early stage, the response to treatment is generally much better. However, the majority of patients face challenges because their disease is found later. Even with aggressive treatment that includes surgery and chemotherapy, along with newer therapies like anti-angiogenic drugs and PARP inhibitors, most patients with stage III-IV disease will eventually experience recurrence. The median time before cancer returns (called progression-free survival) is approximately 13.8 months for patients with advanced-stage disease who didn’t benefit from optimal initial surgery.^[7]

Several factors can influence an individual’s prognosis. Certain gene expression patterns identified in tumor tissue have been linked to survival outcomes. Research has categorized tumors into four distinct subtypes based on their gene expression and DNA methylation patterns, and these subtypes are associated with different survival expectations. Patients whose tumors show the poorest gene expression pattern may have survival times that are 23% shorter than other patients.^[2]

Interestingly, patients who have BRCA1 or BRCA2 gene mutations actually tend to have better survival odds compared to those without these mutations, even though carrying these genes increases the initial risk of developing ovarian cancer. Approximately 21-25% of high-grade serous carcinoma cases have these genetic changes.^[2]^[5] This improved prognosis may relate to how BRCA-mutated cancers respond to certain treatments, particularly platinum-based chemotherapy and PARP inhibitor drugs.

The completeness of initial surgery also dramatically affects outcomes. Patients who undergo surgery that removes all visible tumor (called complete cytoreduction with no residual tumor) have significantly better prognosis than those with remaining disease after surgery. Age, overall health status, and how well patients can tolerate treatment also play important roles in determining individual outcomes.

Survival Rate

Survival rates for ovarian cancer vary widely depending on the stage at diagnosis. When high-grade serous ovarian carcinoma is diagnosed at an early stage and treated appropriately, it responds well to treatment and survival rates are considerably higher. However, because most cases are diagnosed at later stages, overall survival statistics reflect this more challenging reality.

For women with advanced-stage disease who receive the current standard treatment approach—which combines surgery with platinum and taxane chemotherapy, potentially including bevacizumab or PARP inhibitors—outcomes have improved compared to historical rates. However, the disease remains very serious, particularly because recurrence is common. After recurrence, management becomes increasingly challenging, with treatments focused on controlling the disease and maintaining quality of life rather than cure.^[7]

It’s important to understand that survival statistics are based on large groups of patients and represent averages. Individual outcomes can vary significantly based on the specific characteristics of each person’s cancer, their overall health, the treatments available, and how their cancer responds to therapy. Newer treatments continue to be developed and tested in clinical trials, offering hope for improved outcomes in the future.

#1 Clinical Trials Search in Europe